Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (91-100 of 247) with videos related to

Pageof 25
Sort By:
Breast Cancer Research : BCR|March 4, 2024
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancerJordi Rodón, David Demanse, Hope S Rugo, et al.
Cancer Investigation|February 18, 2010
Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortiumJohn D Hainsworth, Anthony A Meluch, Cassie M Lane, et al.
Clinical Advances in Hematology & Oncology : H&O|April 9, 2011
A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumorsSuzanne F Jones, Johanna C Bendell, Jeffrey R Infante, et al.
Cancer Chemotherapy and Pharmacology|June 1, 2011
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabineJeffrey R Infante, Suzanne F Jones, Johanna C Bendell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumorsChristopher J Sweeney, E Gabriela Chiorean, Claire F Verschraegen, et al.
Clinical Breast Cancer|November 26, 2009
A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancerDenise A Yardley, Howard A Burris, David R Spigel, et al.
Journal of Clinical Pharmacology|September 29, 2011
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancerManish Gupta, Patricia M Lorusso, Bei Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network studyF Anthony Greco, Howard A Burris, Sharlene Litchy, et al.
The Oncologist|October 27, 2005
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trialF Anthony Greco, Dana S Thompson, Lisa H Morrissey, et al.
The Oncologist|November 25, 2004
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trialF Anthony Greco, Gladys I Rodriguez, Don W Shaffer, et al.
Pageof 25

Showing results (91-100 of 247) with videos related to

Sort By:
Pageof 25
Breast Cancer Research : BCR|March 4, 2024
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancerJordi Rodón, David Demanse, Hope S Rugo, et al.
Cancer Investigation|February 18, 2010
Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortiumJohn D Hainsworth, Anthony A Meluch, Cassie M Lane, et al.
Clinical Advances in Hematology & Oncology : H&O|April 9, 2011
A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumorsSuzanne F Jones, Johanna C Bendell, Jeffrey R Infante, et al.
Cancer Chemotherapy and Pharmacology|June 1, 2011
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabineJeffrey R Infante, Suzanne F Jones, Johanna C Bendell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumorsChristopher J Sweeney, E Gabriela Chiorean, Claire F Verschraegen, et al.
Clinical Breast Cancer|November 26, 2009
A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancerDenise A Yardley, Howard A Burris, David R Spigel, et al.
Journal of Clinical Pharmacology|September 29, 2011
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancerManish Gupta, Patricia M Lorusso, Bei Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network studyF Anthony Greco, Howard A Burris, Sharlene Litchy, et al.
The Oncologist|October 27, 2005
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trialF Anthony Greco, Dana S Thompson, Lisa H Morrissey, et al.
The Oncologist|November 25, 2004
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trialF Anthony Greco, Gladys I Rodriguez, Don W Shaffer, et al.
Pageof 25